{"id":21308,"date":"2022-05-04T09:10:13","date_gmt":"2022-05-04T07:10:13","guid":{"rendered":"https:\/\/idibell.cat\/?p=21308"},"modified":"2022-05-04T09:25:08","modified_gmt":"2022-05-04T07:25:08","slug":"un-assaig-clinic-mostra-la-seguretat-i-el-potencial-dun-virus-oncolitic-contra-el-cancer-de-pancrees-avancat","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2022\/05\/un-assaig-clinic-mostra-la-seguretat-i-el-potencial-dun-virus-oncolitic-contra-el-cancer-de-pancrees-avancat\/","title":{"rendered":"Un assaig cl\u00ednic mostra la seguretat i el potencial d\u2019un virus oncol\u00edtic contra el c\u00e0ncer de p\u00e0ncrees avan\u00e7at"},"content":{"rendered":"

Els virus oncol\u00edtics son virus modificats gen\u00e8ticament per recon\u00e8ixer i atacar les c\u00e8l\u00b7lules tumorals. Es tracta d’un tipus d’immunoter\u00e0pia innovadora amb un gran recorregut en el tractament contra el c\u00e0ncer. En aquesta l\u00ednia, s’acaben de publicar els resultats d’un assaig cl\u00ednic en fase 1 en el qual es demostra la seguretat del virus oncol\u00edtic VCN-01<\/strong>, i a m\u00e9s, es presenten encoratjadors resultats preliminars de la seva activitat antitumoral<\/strong>.<\/p>\n

L’estudi multic\u00e8ntric liderat pel Dr. Ram\u00f3n Salazar, cap de grup de recerca de l’Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), l’Institut Catal\u00e0 d’Oncologia (ICO), la Universitat de Barcelona, i membre de Centre de Recerca Biom\u00e8dica en Xarxa del C\u00e0ncer (CIBERONC), demostra que l’administraci\u00f3 intravenosa del virus no desencadena efectes adversos importants. Nom\u00e9s en alguns casos, els pacients presenten febre o s\u00edmptomes gripals que acaben revertint.<\/p>\n

Tot i els aven\u00e7os recents, el pron\u00f2stic dels pacients amb c\u00e0ncer de p\u00e0ncrees encara \u00e9s for\u00e7a pobre, amb una superviv\u00e8ncia mitjana inferior a un any. En el present assaig cl\u00ednic, publicat a la revista Journal of ImmunoTherapy of Cancer<\/em><\/a> s’ha fet una aproximaci\u00f3 de l’efic\u00e0cia que tindria la combinaci\u00f3 del virus oncol\u00edtic amb la quimioter\u00e0pia est\u00e0ndard per aquests pacients. Els resultats preliminars mostren que el virus \u00e9s capa\u00e7 d’arribar fins als tumors primaris i les met\u00e0stasis, que \u00e9s actiu i que incrementa l’activitat del sistema immunitari contra els tumors<\/strong>.<\/p>\n

“Les dades obtingudes en aquest assaig cl\u00ednic mostren la seguretat i el potencial de la immunoter\u00e0pia amb el virus VCN-01<\/em> \u2013comenta el Dr. Salazar<\/strong>-. Aquestes dades ja han estat revisades i s’espera poder comen\u00e7ar un assaig cl\u00ednic de fase 2 amb el mateix virus la segona meitat del 2022<\/em>“.<\/p>\n

 <\/p>\n

VCN-01: un virus oncol\u00edtic millorat<\/h3>\n

La utilitzaci\u00f3 de virus oncol\u00edtics en c\u00e0ncers avan\u00e7ats, en els quals ja s’han generat met\u00e0stasi, for\u00e7a a realitzar administracions intravenoses que permetin al virus arribar a totes les localitzacions. Aquest tipus d’administraci\u00f3 presenta certes limitacions, ja que, per una banda, el filtratge al fetge o la melsa redueix la disponibilitat del virus<\/strong>, i per l’altra, augmenten les possibilitats de generar efectes col\u00b7laterals no desitjats<\/strong>.<\/p>\n

El virus VCN-01, propietat de l’empresa VCN Biosciences<\/strong>, start-up sorgida de l’IDIBELL, aborda aquestes limitacions a trav\u00e9s de dues modificacions gen\u00e8tiques claus. Primerament, expressa una prote\u00efna de superf\u00edcie que impedeix que el virus quedi retingut al fetge i que el dirigeix cap al tumor. A m\u00e9s, expressa un enzim que degrada la matriu extracel\u00b7lular del tumor facilitant la propagaci\u00f3 del virus pel tumor i l’acci\u00f3 del sistema immunitari.<\/p>\n

Aquest estudi ha comptat amb la col\u00b7laboraci\u00f3 de l\u00b4Institut Catal\u00e0 d\u00b4Oncologia, l’Hospital Universitari de Bellvitge, l’Hospital Universitario 12 de Octubre, el Centro Integral Oncol\u00f3gico Clara Campal, l’Institut d’Oncologia de la Vall d’Hebr\u00f3n (VHIO), Hsopital Ram\u00f3n i Cajal, Centre Nacional d’Investigaci\u00f3 del C\u00e1ncer (CNIO), la Universitat Pompeu Fabra.<\/p>\n

\u00a0<\/em><\/p>\n

L\u2019Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l’Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l’Institut Catal\u00e0 de la Salut, l’Institut Catal\u00e0 d’Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n

L\u2019IDIBELL \u00e9s membre del Campus d’Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L’any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Els resultats preliminars mostren que el virus \u00e9s actiu, arriba al tumor primari i a les met\u00e0stasis, i desencadena la resposta del sistema immunitari. A m\u00e9s, a les dosis establertes com a recomanades, no desencadena efectes adversos greus.<\/p>\n","protected":false},"author":8,"featured_media":21309,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332,375,447],"tags":[],"class_list":["post-21308","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-colorectal","category-p-de-mecanismes-molelculars-i-terapia-experimental-en-oncologia-oncobell"],"publishpress_future_action":{"enabled":false,"date":"2025-01-25 05:20:30","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/21308","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=21308"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/21308\/revisions"}],"predecessor-version":[{"id":21310,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/21308\/revisions\/21310"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/21309"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=21308"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=21308"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=21308"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}